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Abstract
Background: Low levels of adiponectin, an adipocytokine with anti-diabetic, antiatherogenic and cardioprotective
properties, is associated with increased risk of coronary disease in young men. Previous studies have demonstrated
that smokeless tobacco is linked with a reduction of plasma adiponectin levels. However, the influence of
smokeless tobacco (dipping tobacco) on plasma adiponectin levels still remains unknown. This study was
conducted to assess the plasma adiponectin levels in young men who were using dipping tobacco.
Methods: This was a community based study, which consisted of 186 young lean healthy males aged 20 to
35 years. Among these, 96 men were dipping tobacco users (BMI = 23.07 ± 2.68) and 90 were non-dipping
tobacco users (BMI = 23.67 ± 1.46). Serum adiponectin levels were assessed by Enzyme Linked ImmunoSorbent
Assay (ELISA).
Results: A statistically significant difference in the mean adiponectin level between tobacco dipper and non-dipper
groups was observed (p = 0.0001). A significant difference between the two groups was also observed in
baseline parameters including triglyceride and random blood sugar levels (p < 0.05). However, no significant
difference was observed between the two groups in other clinical parameters.
Conclusions: Findings of this study suggest that dipping tobacco use was significantly associated with low
level of adiponetin in community dwelling young males. This emphasizes the importance of developing
community intervention to reduce the use of dipping tobacco, which will reduce the tobacco associated
disease burden in the community and will improve public health.
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Background
The adipocyte derived plasma protein adiponectin, also
called ARCP30, ADIpoQ, apM1 or GBP28 is a 247
amino acid peptide that accounts for about 0.05 % of
total serum proteins [1–3]. The normal concentration
of adiponectin in plasma ranges from 5 to 30 μg/ml in
males, whereas a higher concentration is found in fe-
males [4]. Adiponectin is an important molecule shown
to be involved in obesity, metabolic syndrome, cardio-
vascular disease, lipid metabolism, and hypertension
[5–8]. Lower levels of circulating adiponectin have
recently been shown to be associated with a number of
conditions in humans. Prominent among them are
coronary artery disease, myocardial infarction, athero-
sclerosis, re-stenosis after percutaneous coronary inter-
vention, type 2 diabetes mellitus as well as hypertension
[2, 5, 9–13]. Recent studies suggest that adiponectin has
anti-atherogenic and anti-inflammatory properties. It is
involved in the lowering of many anti-inflammatory cyto-
kines such C-reactive protein, tumor necrosis factor-α and
interleukin-6 [14–18].
Tobacco use is a significant contributing risk factor for
non-communicable diseases leading to approximately six
million deaths worldwide every year [19]. The increasing
trend of tobacco use in developing countries is alarming,
where 80 % of deaths are expected to occur in next few
decades due to toabcco use. [20]. In south Asian coun-
tries, the prevalence of tobacco use was estimated to be
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72.3, 60.0, 47.3, 34.7, 34.1, 33.6 and 31.6 % in Indonesia,
Bangladesh, Maldives, Cambodia, India and Pakistan, re-
spectively [21].
Similar to that of smoking tobacco, smokeless tobacco
use was also found equally harmful in a variety of dis-
eases. Kumada et al., reported that coronary artery
disease (CAD) was more prevalent in patients with
hypoadiponectemia (less than 4 μg/mL) irrespective of
other known risk factors like diabetes mellitus, dyslipid-
emia, hypertension, smoking habit, and BMI in male
subjects [10]. Huhtasaari et al., reported smokeless to-
bacco as a possible risk factor for myocardial infarction
in a population based study performed on middle-aged
men [22]. Smokeless tobacco was also found to be associ-
ated with hypertension in rural Indians [2]. A significant
increase in both systolic and diastolic blood pressure was
observed in young male population using smokeless
tobacco compared to non-users [23]. Wolk et al., reported
that nicotine of spit tobacco induced catecholamine
release from the adrenal medulla which in turn causes
increase in heart rate and blood pressure [24]. Smokeless
tobacco (Naswar) use and its association with cancer is
well documented. The data from Pakistani hospitals
specialized in treating cancer patients showed that 9.9 %
of all cancer patients were suffering from oropharyngeal
cancer. In addition, with 23.6 % being smokers and 37.4 %
being smokeless tobacco users [25].
Smokeless tobacco has not gained the attention of
the scientific research community in comparison to
smoking, though its use is common all over the world.
Majority of dipping tobacco users believe that it is less
harmful and that its use can go unnoticed. Dipping to-
bacco and other forms of smokeless tobacco are widely
used in some populations. Grinded tobacco leaves in
moist powdered form make dipping tobacco, which is
kept between the lower lip and gum and discarded after
about 15–30 min. In the local language (Pashto), it is
called Naswar (dipping tobacco/moist snuff ). It is avail-
able locally as loose meshed ground tobacco or as
sachets in the developed world.
Peshawar is the capital city of Khyber Pakhtunkhwa,
where the vast majority of ethnic Pashtoons reside where
43.79 % of males and 4.4 % of females use dipping tobacco
[26]. Several studies have suggested the association of
smoking with low levels of adiponectin in plasma, but data
regarding dipping tobacco is lacking. Therefore, a case
control study was conducted in community dwelling
young males to determine if there was any correlation of
dipping tobacco usage and levels of plasma adiponectin.
Methods
Study design
This was a case control study. The study population con-
sisted of 186 young, lean and apparently healthy male
adults. The study participants were divided in to two
groups: dipping tobacco users (n = 96) and non-dipping
tobacco users (n = 90). Inclusion criteria were: healthy in-
dividuals between 20 and 35 years of age and body mass
index (BMI) in the range of 20–25 kg/m2. The cases (dip-
ping tobacco users) were those who had history of taking
dipping tobacco on a daily basis for a minimum of 5 years
regularly with an average of one packet (approximately
50–60 g/day). The controls (non-dippers) were selected
from similar matched socio-demographic background and
were young healthy subjects with no history of using dip-
ping tobacco or tobacco use by other means. In addition,
these control participants were matched to case partici-
pants in terms of age and BMI. All the cases and controls
selected were young, healthy, lean subjects to remove the
possibility of obesity induced hypoadiponectemia or risk
of aging associated derangements in physical and bio-
chemical parameters. A structured questionnaire was used
in each face to face interview to obtain the relevant infor-
mation. The study participants were evaluated by medical
history for use of alcohol, by physical examination for
obesity (BMI >25 kg/m2), and routine clinical laboratory
investigations to exclude individuals with type 2 diabetes,
anemia, liver diseases, chronic renal failure and cardiovas-
cular diseases. Past dipping tobacco users, and subjects
with BMI more than 25 were excluded from the study.
Study participant on drug(s) which alter hormone levels
were also excluded from the study. The prevalence of dip-
ping tobacco among women was very low around 4.4 %
and the access to women was difficult due to traditional
and cultural restrictions in this area, therefore, women
were also excluded from the study [26, 27]. The study was
approved by the institution ethical committee of Khyber
Medical University, Pakistan. After the nature of the study
was explained in detail, informed consent was obtained
from all participants.
Anthropometric parameters
Anthropometric data (weight & height) of the study sub-
jects were collected and BMI was calculated as kg/m2.
Resting blood pressure was measured using a standard
mercury sphygmomanometer. Two blood pressure read-
ings were taken with the participant resting for 10 min,
and the mean of the two readings was calculated and
used for data analysis.
Laboratory measurement
Non-fasting venous blood samples (10 ml divided into
two 5 ml tubes) were collected in sterile syringes using
aseptic technique. The samples were immediately trans-
ported to the laboratory (within 2 h) in ice cooled con-
tainers for further examination. Serum was separated after
centrifugation at 12,000 × g and stored at −20 °C for sub-
sequent analysis. Total cholesterol (TC), triglyceride (TG),
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high-density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), random blood sugar,
serum creratinin were measured in both cases and control
groups with a standard protocol using semi-automated
chemistry analyzer COBAS C111 (Roche) and kits from
the same company.
Adiponectin assay
Serum low molecular weight adiponectin concentra-
tion was determined by ELISA method using the kits
supplied by Glory Science Co., Ltd. Research (Del
Rio, TX 78840, USA). The kit uses double-antibody
sandwich ELISA to assess the level of human adiponectin
in serum samples. The wells were pre-coated with human
adiponectin monoclonal antibodies. The secondary anti-
bodies consisted of adiponectin antibodies labelled with
biotin, and combined with streptavidine-HRP to form an
immune complex. After washing completely, 3,3′,5,5′-tet-
ramethylbenzidine (TMB) liquid substrate was added. The
TMB substrate changed a blue color when HRP enzyme
catalyzed the reaction. The reaction was terminated by the
addition of a stop solution and the color change was mea-
sured at a wavelength of 450 nm. All the steps of the assay
were done according to the manufacturer’s instructions.
The results were analyzed by three independent re-
searchers, blinded to the clinico-demographic data of
study participants to remove subjective bias. The concen-
tration of adiponectin in the sample was determined by
comparing the optical densities of the samples from the
standard calibration curve with negative controls. Adipo-
nectin samples were run in duplicate and mean values
were calculated for each sample.
Statistical analysis
Means or proportions of clinical characteristics were ana-
lyzed for each group in the study. All data was expressed
as means ± standard deviation. Differences between groups
were examined for statistical significance using the stu-
dent’s t-test, p ≤ 0.05 was considered statistically significant.
Unpaired t-test (independent sample t test) was used to
examine the differences in adiponectin levels between the
two groups. All analyses were performed using SPSS soft-
ware, version 19 “SPSS (IBM, Armonk, NY, USA).”
Results
The study participants were primarily of Pashtoon ances-
try, living in the north western areas of Pakistan with the
majority using dipping tobacco (about 64 %). The subjects
in this study comprised of a total of 186 young, lean, male
adults, who were apparently healthy. Among these sub-
jects 96 were dipping tobacco users (28.84 ± 4.77 years
old), 90 were non-dipping tobacco users (28.41 ± 4.99 years
old), with age range from 20 to 35 years.
Table 1 summarizes the baseline characteristics of
each participant. Significant changes in some clinical
parameters were observed between cases and control
groups while in others, no significant variations were
observed. BMI was 23.07 ± 2.68 kg/m2 in the dipping
tobacco users while it was 23.67 ± 1.46 kg/m2 in the non-
users. Systolic and diastolic blood pressure in tobacco dip-
pers and non-dippers:119.8 ± 9.67 and 118.61 ± 8.51;
80.36 ± 9.60 and 79.5 ± 8.74 mmHg respectively showing
no significant difference. Serum creatinin was 0.78 ± 0.09
in dippers as compared to non-dippers 0.78 ± 0.08 mg/dl
(p = 0.94). The values of triglycerides were 127.39 ± 33.43
in dippers and 113.81 ± 28.57 mg/dl in non-dippers
(p = 0.003) showing highly significant difference be-
tween the two study groups. Similarly, the values of
HDL-C were 48.28 ± 3.74 and 47.22 ± 6.48 mg/dl in
dippers and non-dippers respectively (p = 0.171). The level
of random blood sugar in dippers was 101.8 ± 15.46 and
96.54 ± 10.06 mg/dl in non-dippers (p = 0.013). The level
Table 1 Baseline characteristics of young adults in dipping tobacco users and nondippers
Characteristics Dippers (n = 96) Nondippers (n = 90) p value
Age (years) mean ± SD 28.84 ± 4.77 28.41 ± 4.99 0.547
BMI, mean ± SD, kg/m2 23.07 ± 2.68 23.67 ± 1.46 0.060
Systolic blood pressure, mean ± SD, mmHg 119.8 ± 9.67 118.61 ± 8.51 0.379
Diastolic blood pressure, mean ± SD, mmHg 80.36 ± 9.60 79.5 ± 8.74 0.523
Random blood sugar, mean ± SD, mg/dl 101.79 ± 15.46 96.54 ± 10.06 0.013
Serum creatinine, mean ± SD, mg/dl 0.78 ± 0.09 0.78 ± 0.08 0.941
Total cholesterol, mean ± SD, mg/dl 161.38 ± 19.53 161.16 ± 25.22 0.947
TG, mean ± SD, mg/dl 127.39 ± 33.43 113.81 ± 28.57 0.003
HDL cholesterol, mean ± SD, mg/dl 48.28 ± 3.74 47.22 ± 6.48 0.171
LDL cholesterol, mean ± SD, mg/dl 113.10 ± 18.14 108.70 ± 23.11 0.149
Serum adiponectin, mean ± SD, μg/ml 3.23 ± 2.07 12.94 ± 10.50 0.0001
Abbreviations: BMI Body Mass Index, TG Triglycerides, HDL High Density Lipoproteins, LDL Low Density Lipoproteins. For these variables, data are presented as
mean ± SD and student’s t- test was applied. The letters in bold shows the significant difference between the two study groups
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of LDL-C was 113.10 ± 18.14 in dippers and 108.70 ±
23.11 mg/dl in non-dippers (p = 0.149) showing statisti-
cally no significant difference.
Figure 1 shows the scatter plots of the difference in
the level of random blood sugar and triglycerides be-
tween the dipping tobacco users and non-dippers. It
is clear that the level of random blood sugar signifi-
cantly changed (p = 0.013) in dippers as compared to
non-dippers (Fig. 1a). Similarly, the values of triglyc-
erides were also significantly changed (p = 0.003) in
both groups (Fig. 1b).
Figure 2 shows adiponectin levels in dippers and
non-dippers. The most promising finding in our
study was the low level of adiponectin in dippers
compared to those of non-dippers. The mean serum
adiponectin level was 3.23 ± 2.07 in dippers, while it
was 12.94 ± 10.50 in non-dippers (p = 0.0001, inde-
pendent sample t test). Thus a statistically significant
lower level of serum adiponectin was observed in
dippers compared to non-dippers. No association of
adiponectin was observed with other clinical parame-
ters, e.g. hypertension, HDL-C and raised triglyceride
in both tobacco dippers and non-dippers.
Discussion
This study was designed to assess the effect of dipping
tobacco use on serum adiponectin concentration. Our
results showed a significantly lower serum adiponectin
level in healthy young males who were using dipping
tobacco for a minimum of 5 years regularly with an aver-
age of one packet (approximately 50–60 g) daily. In
contrast to the published literature we did not find any
association of lower adiponectin with hypertension (both
systolic and diastolic), serum creatinin, total cholesterol,
LDL-C and HDL-C levels [27, 28]. The discrepancies in
these parameters might probably be due to the inclu-
sion of young lean adults in the current study. The
present study is therefore unique because we consid-
ered lean young individuals who were in the highly
productive and highly resistant ages of their lives
compared to previous studies which included subjects
with age above 40 years [27–29]. The clinical parame-
ters including blood pressure, serum creatinin, total
cholesterol, LDL-C and HDL-C were not significantly
different in dipping tobacco users relative to those of
age matched non-dipping control group (Table 1).
The level of adiponectin is reported to increase in neph-
ritic and renal failure [30, 31]. Therefore, we measured
serum creatinin in order to exclude any renal dysfunction
in our study groups. Astonishingly, we did not detect any
significant change in the levels of HDL-C, LDL-C, serum
creatinine and total cholesterol in the present study.
The levels of triglyceride were significantly different
between tobacco dippers and non-dippers (Table 1
shown in bold face letter). Our results support the
previous literature where adiponectin was found to be
inversely associated with triglyceride levels [32, 33].
It has been reported previously that cigarette smoking is
associated with low plasma adiponectin levels [9, 34],
however, to the best of our knowledge, no study has ex-
plored the relationship between smokeless tobacco use
and serum adiponectin level in young adult males. There-
fore, we hypothesized that similar to smoking tobacco;
smokeless tobacco might be associated with low level of
adiponectin in community-dwelling young adults. Our
results support the previous literature on tobacco induced
hypo-adiponectemia. Kawamoto et al., reported signifi-
cantly lower adiponectin level in community dwelling
Japanese men aged 20 to 89 years using smoking tobacco
[27]. An interesting study showed a significant difference
Fig. 1 Scatter plots of serum random blood sugar (a) and triglyceride (b) (individual’s data for each subject) in smokeless tobacco dippers (n = 96) and
non-dippers (n = 90). The horizontal lines represent the means between the tobacco dippers and non-dippers. P values represent the significance of
the effect of random blood sugar (a) triglyceride (b) levels between the two study groups
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in adiponectin level in current smokers, those who have
stopped smoking and those who had never smoked [9].
Importantly, some studies have shown an increase in
plasma adiponectin level following cessation of smoking
[35, 36]. In a study by Otsuka et al., cessation of smok-
ing was associated with increased plasma adiponectin
level in 47 non smokers and 25 current smokers with a
6 month follow-up period [35]. Barrios et al. reported
that low level of adiponectin (≤4.5 μg/mL) is associated
with adverse cardiovascular health [37], though the
mean age and BMI of our study participants was less
than than the participants of that study.
These findings have led us to explore new possibil-
ities of the association between dipping tobacco and
plasma adiponectin levels. Adiponectin is a major con-
tributor in insulin sensitivity and in decreasing the risk
of diabetes and coronary heart diseases. Dipping to-
bacco is commonly used in ethnic Pashtoon areas in
Pakistan and Afghanistan. Our study showed an inverse
relationship of dipping tobacco with adiponectin level.
Clearly, this association would lead to adverse cardio-
vascular health. Thus this novel finding could help the
general public and health authorities understand the asso-
ciation of dipping tobacco with adverse cardiovascular
health. In addition, this study will also help designing
future studies on exploring the underlying molecular
mechanisms responsible for hypoadiponectemia.
Our study has certain limitations. In this study we
were unable to compare our results with individuals
using smoking tobacco. The inclusion of smoking to-
bacco group would have made the results of this study
more informative. This would have provided us with
evidence on adiponectin level in three groups: dipping
tobacco users; smoking tobacco users; and both dip-
ping and smoking tobacco users. However, due to lim-
ited funding we were not able to accomplish this part
of the study but we plan to explore this aspect in a future
study. In addition, the smokeless tobacco was not bio-
chemically verified. Adiponectin may lower C-reactive
proteins as well as a variety of other inflammatory bio-
markers as previously reported [14–18]. However, we
were not able to measure the levels of these inflammatory
biomarkers in our study. Another limitation of our
study was the non-fasting venous blood sampling due
to restricted access to individuals and to convince
them for providing fasting blood samples. We were
also unable to assess the dose dependent response of
dipping tobacco in changing the biochemical parame-
ters. Thus to explore the aforementioned associations
future studies are recommended.
Conclusions
This study showed that the serum adiponectin levels
were significantly lower in the dipping tobacco users as
compared to non-users in adult lean males. These find-
ings support a critical association of hypoadiponectemia
with dipping tobacco use in community-dwelling youth.
Consequently, the results of this study provide evidence
that will increase the awareness of the general public
regarding the adverse effects associated with dipping
tobacco use. This will also hopefully help the public
health authorities in deciding what measures to take to
reduce the use of dipping tobacco and reduce the associ-
ated health burden. Moreover, as the level of adiponectin
is significantly lowered in dipping tobacco users than
non-dippers, it might aid in the early diagnosis of clin-
ical situations (e.g. cardiovascular health).
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